Kymera's Eczema Drug Gets Fast Track Designation in the United States

KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.

Zacks Investment Research • Dec 12, 2025

Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the closing of its upsized underwritten public offering of $602.0 million of shares of its common stock. Kymera sold and issued 8,050,000 shares of its common stock, which includes 1,050,000 shares sold and issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock. The shares of common stock were sold at a public offering price of $86.00 per share. The gross proceeds to Kymera from the offering were approximately $692.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera.

GlobeNewsWire • Dec 11, 2025

KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study

Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.

Zacks Investment Research • Dec 9, 2025

This Drugmaker's Stock Is Soaring Over 40% Monday

Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high Monday afternooon after the drugmaker reported positive results from an early test of an oral anti-inflammatory drug.

Investopedia • Dec 8, 2025

Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?

Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.

Investors Business Daily • Dec 8, 2025

Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript

Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript

Seeking Alpha • Dec 8, 2025

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients

GlobeNewsWire • Dec 8, 2025

Kymera Therapeutics Announces Proposed Public Offering

WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares of common stock to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

GlobeNewsWire • Dec 8, 2025

Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum

Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile, rapid onset, and meaningful biomarker and symptom improvements, supporting advancement to Phase 2b trials in AD and asthma. KYMR's $4.8B market cap reflects its validated protein-degradation platform and KT-621's commercial potential in large, crowded Type-2 inflammatory disease markets.

Seeking Alpha • Dec 8, 2025

Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug.

The biopharma company is counting on KT-621 to treat patients with Type 2 inflammatory diseases.

Barrons • Dec 8, 2025